About this trial
This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder. Eptacog beta (EB) is not currently approved by the U.S. Food and Drug Administration (FDA) for this condition.
The study will assess the effectiveness and safety of eptacog beta (EB) when used to treat serious bleeding events, and in an optional phase, when used routinely to prevent bleeding. During the first three (3) months, participants will manage any bleeding episodes with their standard treatment (e.g., factor products or platelet transfusions). After this initial period, they will use the study drug to treat serious bleeding events.
Participants will have approximately 4 to 5 visits with their hematologist over the 9-month study period. They will also be asked to complete a diary documenting bleeding episodes and treatments, and to answer questions about how bleeding affects their daily life. Blood samples will be collected to monitor their condition and any potential side effects of the study drug.
At the end of the main study, participants will have the option to enter an optional extension phase, where they will receive routine intravenous infusions of the study drug 2 to 3 times per week for 6 months to help prevent future bleeding episodes and complications.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult or Pediatric persons with inherited Glanzmann thrombasthenia (see diagnostic criteria below)
Severe bleeding phenotype
Adequate hepatic function
Adequate renal function
Disqualifiers
Thrombocytopenia (platelet count < 100k)
Acquired Glanzmann thrombasthenia secondary to autoimmune disease, malignancy, or medication
Inherited or acquired bleeding diathesis other than Glanzmann thrombasthenia
Have a history of venous or arterial thrombotic event within 2 years of study enrollment
Trial design
Single group
Treatments tested in this trial
EPTACOG BETA
DrugEptacog beta (SEVENFACT®; EB) is a lyophilized powder in single-use vials (1, 2, or 5 mg) of coagulation factor VIIa (recombinant)-jncw. It is reconstituted with sterile water (provided in the kit) and administered intravenously. SEVENFACT® may be administered by a healthcare provider (HCP) at the study site or home, or by a trained participant/caregiver. Participants will be monitored in a healthcare facility for 60 minutes after the first dose for hypersensitivity.
Treatment groups
Trial outcomes
Primary outcomes
Proportion of bleeding events successfully treated within 24 hours of the first Eptacog Beta (EB) administration
Proportion of acute bleeding events successfully treated with EB within 24 hours of the first EB administration based on an "excellent or good" response on a 4-point hemostatic efficacy scale and without rebleeding before 36 hours. Hemostatic Efficacy Scale: None = No effect; bleeding unchanged or worsened; continued treatment needed. Moderate = Some effect (e.g., pain decreased, bleeding signs improved) but bleeding continued; further treatment needed. Good = Bleeding symptoms are largely reduced but not completely resolved; no further EB infusions are needed. Excellent = Full relief of bleeding symptoms; no additional EB infusion required.
Number of bleeding events over the study period
The number of bleeding events occurring while receiving routine EB prophylaxis will be compared with the number of bleeding events that occurred during on-demand therapy. \*This outcome applies only to the optional interventional prophylaxis phase.
Secondary outcomes
Number of treatment-Emergent Adverse Events and Clinically Significant Laboratory Abnormalities
Safety of EB will be measured by the number of treatment-emergent adverse events, treatment-emergent serious adverse events, and treatment-emergent potentially clinically significant laboratory values reported during the interventional phases compared to those reported during the non-interventional observational phase.
EuroQol five-dimensional questionnaire for youth (EQ-5D-Y) score for participants 4-15 years of age.
The EQ-5D-Y-5L is a child-friendly, five-dimension, five-level instrument assessing: Mobility, Looking After Myself, Doing Usual Activities, Having Pain or Discomfort, and Feeling Worried, Sad, or Unhappy. Each dimension has five response levels (1 = no problems to 5 = extreme problems/unable to do). Respondents select one statement per dimension describing their health on the assessment day, forming a 5-digit profile summarizing their health state. For example, code 11234 indicates no problems with mobility or looking after myself, slight problems doing usual activities, some pain or discomfort, and feeling very worried, sad, or unhappy. Higher scores reflect greater severity. \*15 months applies to the optional phase only.
EuroQol five-dimensional 5 Level (EQ-5D-5L) score for participants ≥16 years
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It captures how people feel across five dimensions, each of which has five levels: 1 = no problems to 5 = extreme problems/unable to do. The five answers produce a unique 5-digit health state, for example, 11234, that describes the young person's health state. For example, the code 11234 describes a health state where there are no problems with walking about (mobility) or looking after myself, a little bit of a problem with doing usual activities, some pain or discomfort, and feeling really worried, sad, or unhappy. \*15 months applies to the optional phase only.
Patient Reported Outcomes Measurement Information System (PROMIS) fatigue short form for adults
The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal and assess fatigue over the past seven days. PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. Higher scores equal more fatigue. \*15 months applies to the optional phase only.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Emory University
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Collaborator